Poly Medicure · NSE: POLYMED · BSE: 531768

Q1 FY23 results · Apr–Jun 2022

Poly Medicure reported revenue from operations of ₹248.85 crore (up 17.4% from Q1 FY22) and net profit of ₹26.96 crore (down 28.3% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY23Q1 FY22YoYQ4 FY22QoQ
Revenue from operations248.85211.94+17.4%257.52−3.4%
Other income4.5710.27−55.5%8.20−44.2%
Total income253.42222.21+14.0%265.71−4.6%
Profit before share of associates & JVs and tax35.8949.54−27.6%48.51−26.0%
Share of profit/(loss) of associates & JVs0.400.650.28
Net profit for the period26.9637.59−28.3%36.17−25.4%
EPS, basic (₹)2.813.92−28.3%3.77−25.5%
Net margin (%)10.817.714.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY23Q1 FY22YoYQ4 FY22QoQ
Revenue from operations239.01202.97+17.8%244.44−2.2%
Other income4.5810.23−55.3%9.00−49.2%
Total income243.58213.20+14.2%253.44−3.9%
Profit before tax38.1348.63−21.6%51.02−25.3%
Net profit for the period28.8036.03−20.1%38.44−25.1%
EPS, basic (₹)3.003.76−20.2%4.01−25.2%
Net margin (%)12.017.815.7
Consolidated
Filed with BSE
05 Aug 2022, 10:13 IST
Board meeting
04 Aug 2022
Period
01 Apr 2022 to 30 Jun 2022
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
05 Aug 2022, 10:13 IST
Board meeting
04 Aug 2022
Period
01 Apr 2022 to 30 Jun 2022
Review status
Unaudited
Source
XBRL filing on BSE